glp 1 sexual side effects Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease desire, and a biopsychosocial model for why we don't 'see' it How GLP-1 Drugs Affect Libido,

Incretin-based therapy and the risk of diabetic foot ulcers and related events

Overeating can lead to weight gain if the person consumes more calories than they burn off

Tirzepatide (weekly injectable) Dosing frequency: Once weekly, same day each week Half-life: approximately 5 days (120 hours) Peak concentration: 8 to 72 hours after injection Recommended timing approach: The shorter half-life compared to semaglutide means the end-of-week trough is more noticeable

Employees have a rolling Special Enrollment window to come off large group anytime for the first of the month

Realistic 2026 Results: What the Data Shows Metric Typical IF Outcome (1012 Weeks) Weight Loss 711 pounds (roughly 35% of body weight) Fat Loss Primarily visceral (belly) fat Blood Pressure Significant reductions in those with high baseline levels Muscle Retention High (if paired with resistance training) Reduced calorie intake due to fewer meals Improved insulin sensitivity Increased fat burning during fasting periods However, IF does not directly suppress appetite, which is why many people struggle with hunger during fasting hours

If an individuals diabetes is poorly controlled, they might be more susceptible to complications during or after donation, such as fluctuations in blood sugar, dizziness, or prolonged recovery